INFLUENZA VACCINES MARKET ANALYSIS

Influenza Vaccines Market, By Vaccine Type (Inactivated, Live Attenuated), By Valency (Quadrivalent, Trivalent), By Route of Administration (Injection, Nasal Spray), By Age Group (Paediatrics, Adults), By Technology (Egg-Based Flu Vaccines, Cell Culture-Based Flu Vaccines, Recombinant Flu Vaccines), By Distribution Channel (Public, Private), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

Published In : Mar 2024
Code : CMI1705
Pages :197
Formats :
Excel and PDF
Industry : Biotechnology

Regional Analysis

Influenza Vaccines Market Regional Insights

To learn more about this report, request sample copy

North America has dominated the global influenza vaccines market for many years due to strong healthcare infrastructure and awareness among people regarding the importance of vaccination and is estimated to hold 49.5% of the market share in 2024. The U.S. accounts for the largest share within the region owing to the presence of major vaccine manufacturers and adoption of mandatory vaccination programs by healthcare facilities. Several manufacturers have their headquarters in the U.S. and undertake large scale production to meet domestic demand. In addition, vaccination rates have been steadily rising both among pediatric and adult populations.

However, Asia Pacific region is emerging as the fastest growing market for influenza vaccines worldwide. Expanding healthcare infrastructure, growing per capita healthcare expenditure and increasing focus of governments on immunization programs are some key factors driving market growth. Countries like China, India and Japan are at the forefront due to their large population base and initiatives by public health organizations to spread awareness. Vaccine sales are rising sharply in Asia driven by changing lifestyles and growing cases of influenza-related illnesses in recent years.